Glioblastoma and Individualized Therapies
- Conditions
- Glioma, Malignant
- Registration Number
- NCT05356312
- Lead Sponsor
- Zentrum fur Humangenetik Tuebingen
- Brief Summary
The treatment of patients with World Health Organization (WHO) grade 4 malignant glioma has not seen any significant breakthrough the past years. Following surgery and radio / chemotherapy patients still experience a very high recurrence risk and the prognosis is dismal. The investigators observed patients with grade IV malignant glioma receiving individualized treatment based on their molecular profile including fully personalized vaccines.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- malignant glioma, IDH WT
Exclusion Criteria
- na
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Zentrum für Humangenetik Tübingen
🇩🇪Tübingen, Germany